These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 29688503)

  • 1. The potential benefits of aspirin for primary cardiovascular prevention in rheumatoid arthritis: a secondary analysis of the PRECISION Trial.
    Solomon DH; Libby P; Yeomans ND; Wang Q; Wolski KE; Nissen SE; Husni ME
    Rheumatology (Oxford); 2018 Aug; 57(8):1364-1369. PubMed ID: 29688503
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomised clinical trial: gastrointestinal events in arthritis patients treated with celecoxib, ibuprofen or naproxen in the PRECISION trial.
    Yeomans ND; Graham DY; Husni ME; Solomon DH; Stevens T; Vargo J; Wang Q; Wisniewski LM; Wolski KE; Borer JS; Libby P; Lincoff AM; Lüscher TF; Bao W; Walker C; Nissen SE;
    Aliment Pharmacol Ther; 2018 Jun; 47(11):1453-1463. PubMed ID: 29667211
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiorenal risk of celecoxib compared with naproxen or ibuprofen in arthritis patients: insights from the PRECISION trial.
    Obeid S; Libby P; Husni E; Wang Q; Wisniewski LM; Davey DA; Wolski KE; Xia F; Bao W; Walker C; Ruschitzka F; Nissen SE; Lüscher TF
    Eur Heart J Cardiovasc Pharmacother; 2022 Sep; 8(6):611-621. PubMed ID: 35234840
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Aspirin Coadministration on the Safety of Celecoxib, Naproxen, or Ibuprofen.
    Reed GW; Abdallah MS; Shao M; Wolski K; Wisniewski L; Yeomans N; Lüscher TF; Borer JS; Graham DY; Husni ME; Solomon DH; Libby P; Menon V; Lincoff AM; Nissen SE
    J Am Coll Cardiol; 2018 Apr; 71(16):1741-1751. PubMed ID: 29673465
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of concomitant low-dose aspirin on the safety and tolerability of naproxen and esomeprazole magnesium delayed-release tablets in patients requiring chronic nonsteroidal anti-inflammatory drug therapy: an analysis from 5 Phase III studies.
    Angiolillo DJ; Datto C; Raines S; Yeomans ND
    J Thromb Thrombolysis; 2014 Jul; 38(1):11-23. PubMed ID: 24368727
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Risk of Major NSAID Toxicity with Celecoxib, Ibuprofen, or Naproxen: A Secondary Analysis of the PRECISION Trial.
    Solomon DH; Husni ME; Libby PA; Yeomans ND; Lincoff AM; Lϋscher TF; Menon V; Brennan DM; Wisniewski LM; Nissen SE; Borer JS
    Am J Med; 2017 Dec; 130(12):1415-1422.e4. PubMed ID: 28756267
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differences in Safety of Nonsteroidal Antiinflammatory Drugs in Patients With Osteoarthritis and Patients With Rheumatoid Arthritis: A Randomized Clinical Trial.
    Solomon DH; Husni ME; Wolski KE; Wisniewski LM; Borer JS; Graham DY; Libby P; Lincoff AM; Lüscher TF; Menon V; Yeomans ND; Wang Q; Bao W; Berger MF; Nissen SE;
    Arthritis Rheumatol; 2018 Apr; 70(4):537-546. PubMed ID: 29266879
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rationale, design, and governance of Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen Or Naproxen (PRECISION), a cardiovascular end point trial of nonsteroidal antiinflammatory agents in patients with arthritis.
    Becker MC; Wang TH; Wisniewski L; Wolski K; Libby P; Lüscher TF; Borer JS; Mascette AM; Husni ME; Solomon DH; Graham DY; Yeomans ND; Krum H; Ruschitzka F; Lincoff AM; Nissen SE;
    Am Heart J; 2009 Apr; 157(4):606-12. PubMed ID: 19332185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gastrointestinal and cardiovascular risk of non-selective NSAIDs and COX-2 inhibitors in elderly patients with knee osteoarthritis.
    Turajane T; Wongbunnak R; Patcharatrakul T; Ratansumawong K; Poigampetch Y; Songpatanasilp T
    J Med Assoc Thai; 2009 Dec; 92 Suppl 6():S19-26. PubMed ID: 20128070
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Are COX-2 inhibitors preferable to non-selective non-steroidal anti-inflammatory drugs in patients with risk of cardiovascular events taking low-dose aspirin?
    Strand V
    Lancet; 2007 Dec; 370(9605):2138-51. PubMed ID: 18156036
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of Aspirin in the Primary Prevention of Cardiovascular Diseases and Cancer in the Elderly: A Population-Based Cohort Study in Korea.
    Jung M; Lee S
    Drugs Aging; 2020 Jan; 37(1):43-55. PubMed ID: 31755069
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risks and benefits of COX-2 inhibitors vs non-selective NSAIDs: does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study.
    Rahme E; Nedjar H
    Rheumatology (Oxford); 2007 Mar; 46(3):435-8. PubMed ID: 17255138
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Derivation and Validation of a Major Toxicity Risk Score Among Nonsteroidal Antiinflammatory Drug Users Based on Data From a Randomized Controlled Trial.
    Solomon DH; Shao M; Wolski K; Nissen S; Husni ME; Paynter N
    Arthritis Rheumatol; 2019 Aug; 71(8):1225-1231. PubMed ID: 30801994
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Strategies to optimize treatment with NSAIDs in patients at risk for gastrointestinal and cardiovascular adverse events.
    Scheiman JM; Hindley CE
    Clin Ther; 2010 Apr; 32(4):667-77. PubMed ID: 20435236
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term safety of naproxen and esomeprazole magnesium fixed-dose combination: phase III study in patients at risk for NSAID-associated gastric ulcers.
    Sostek MB; Fort JG; Estborn L; Vikman K
    Curr Med Res Opin; 2011 Apr; 27(4):847-54. PubMed ID: 21319944
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiovascular outcomes in high risk patients with osteoarthritis treated with ibuprofen, naproxen or lumiracoxib.
    Farkouh ME; Greenberg JD; Jeger RV; Ramanathan K; Verheugt FW; Chesebro JH; Kirshner H; Hochman JS; Lay CL; Ruland S; Mellein B; Matchaba PT; Fuster V; Abramson SB
    Ann Rheum Dis; 2007 Jun; 66(6):764-70. PubMed ID: 17412741
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lack of effect of aspirin in primary CV prevention in type 2 diabetic patients with nephropathy: results from 8 years follow-up of NID-2 study.
    Sasso FC; Marfella R; Pagano A; Porta G; Signoriello G; Lascar N; Minutolo R; Carbonara O; Persico M; Piscione F; De Nicola L; Torella R; Paolisso G
    Acta Diabetol; 2015 Apr; 52(2):239-47. PubMed ID: 25109286
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial.
    Farkouh ME; Kirshner H; Harrington RA; Ruland S; Verheugt FW; Schnitzer TJ; Burmester GR; Mysler E; Hochberg MC; Doherty M; Ehrsam E; Gitton X; Krammer G; Mellein B; Gimona A; Matchaba P; Hawkey CJ; Chesebro JH;
    Lancet; 2004 Aug 21-27; 364(9435):675-84. PubMed ID: 15325832
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hospitalization for gastrointestinal bleeding associated with non-steroidal anti-inflammatory drugs among elderly patients using low-dose aspirin: a retrospective cohort study.
    Rahme E; Bardou M; Dasgupta K; Toubouti Y; Ghosn J; Barkun AN
    Rheumatology (Oxford); 2007 Feb; 46(2):265-72. PubMed ID: 16844699
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.